Samchundang Pharmaceuticals announced on November 2 that it has signed an exclusive sales and supply agreement with Japanese pharmaceutical company Daiichi Sankyo Espha for SCD411, a biosimilar for treating macular degeneration, in Japan.

◆ Contract Product SCD411 is a biosimilar with aflibercept as its active ingredient. The products covered by the agreement are a 2mg pre-filled syringe and a vial product. Detailed terms such as the contract value, total milestone payments, and profit sharing were not disclosed by mutual agreement between the two companies.

◆ Roles of the Two Companies Samchundang Pharmaceuticals will hold the Japanese marketing authorization for SCD411 under its own name through the foreign special approval scheme under Article 19-2 of Japan's Pharmaceutical and Medical Device Act. Daiichi Sankyo Espha will serve as the designated marketing authorization holder (D-MAH), handling sales in Japan and maintaining the authorization.

◆ Exclusive Supply Period The exclusive supply period runs from the contract date until 10 years after the product's launch. After that, it will be automatically extended in two-year increments.

[※ This article is for reference in making investment decisions, and the final responsibility for investments lies with the investor.]